Evaluation of hepatotoxicity with off-label oral-treatment doses of voriconazole for invasive fungal infections

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 1, 2011, Pages 184-189

  Gorski, Elizabeth ^a,b   Esterly, John S ^a,b   Postelnick, Michael ^a   Trifilio, Steven ^a   Fotis, Michael ^a   Scheetz, Marc H ^a,b  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; LIVER ENZYME; VORICONAZOLE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG FEVER; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HUMAN; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; OFF LABEL DRUG USE; PRIORITY JOURNAL; SIDE EFFECT; SYSTEMIC MYCOSIS; TREATMENT OUTCOME; VISUAL DISORDER;

AGED; ANTIFUNGAL AGENTS; FEMALE; HUMANS; LIVER; MALE; MIDDLE AGED; MYCOSES; PYRIMIDINES; RETROSPECTIVE STUDIES; TRIAZOLES;

EID: 78650669092     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01078-10     Document Type: Article

References (23)

1. Ascioglu, S., J. H. Rex, B. de Pauw, J. E. Bennett, J. Bille, F. Crokaert, D. W. Denning, J. P. Donnelly, J. E. Edwards, Z. Erjavec, D. Fiere, O. Lortholary, J. Maertens, J. F. Meis, T. F. Patterson, J. Ritter, D. Selleslag, P. M. Shah, D. A. Stevens, and T. J. Walsh. 2002. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis. 34:7-14.
2. Boucher, H. W., A. H. Groll, C. C. Chiou, and T. J. Walsh. 2004. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 64: 1997-2020.
3. Chamilos, G., M. Luna, R. E. Lewis, R. Chemaly, I. I. Raad, and D. P. Kontoyiannis. 2007. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study. Clin. Ther. 29:1980-1986.
4. Charlson, M. E., P. Pompei, K. L. Ales, and C. R. MacKenzie. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40:373-383.
5. den Hollander, J. G., C. van Arkel, B. J. Rijnders, P. J. Lugtenburg, S. de Marie, and M. D. Levin. 2006. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections. J. Antimicrob. Chemother. 57:1248-1250.
6. Deyo, R. A., D. C. Cherkin, and M. A. Ciol. 1992. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J. Clin. Epidemiol. 45:613-619.
7. Guo, J. J., P. R. Wigle, K. Lammers, and O. Vu. 2005. Comparison of potentially hepatotoxic drugs among major US drug compendia. Res. Social Adm. Pharm. 1:460-479.
8. Hyland, R., B. C. Jones, and D. A. Smith. 2003. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab. Dispos. 31:540-547.
9. Johnson, L. B., and C. A. Kauffman. 2003. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis. 36:630-637.
10. Lazarus, H. M., J. L. Blumer, S. Yanovich, H. Schlamm, and A. Romero. 2002. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J. Clin. Pharmacol. 42:395-402.
11. Lee, W. M. 2003. Drug-induced hepatotoxicity. N. Engl. J. Med. 349:474-485.
12. Levin, M. D., J. G. den Hollander, B. van der Holt, B. J. Rijnders, M. van Vliet, P. Sonneveld, and R. H. van Schaik. 2007. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. J. Antimicrob. Chemother. 60:1104-1107.
13. Lucena, M. I., M. Garcia-Cortes, R. Cueto, J. Lopez-Duran, and R. J. Andrade. 2008. Assessment of drug-induced liver injury in clinical practice. Fundam. Clin. Pharmacol. 22:141-158.
14. Pappas, P. G., C. A. Kauffman, D. Andes, D. K. Benjamin, Jr., T. F. Calandra, J. E. Edwards, Jr., S. G. Filler, J. F. Fisher, B. J. Kullberg, L. Ostrosky-Zeichner, A. C. Reboli, J. H. Rex, T. J. Walsh, and J. D. Sobel. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
15. Pascual, A., T. Calandra, S. Bolay, T. Buclin, J. Bille, and O. Marchetti. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46:201-211.
16. Pfizer, Inc. 2008. VFend (voriconazole) package insert. Pfizer, Inc., New York, NY.
17. Scott, L. J., and D. Simpson. 2007. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 67:269-298.
18. Smith, J., N. Safdar, V. Knasinski, W. Simmons, S. M. Bhavnani, P. G. Ambrose, and D. Andes. 2006. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother. 50:1570-1572.
19. Tan, K., N. Brayshaw, K. Tomaszewski, P. Troke, and N. Wood. 2006. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J. Clin. Pharmacol. 46:235-243.
20. Theuretzbacher, U., F. Ihle, and H. Derendorf. 2006. Pharmacokinetic/ pharmacodynamic profile of voriconazole. Clin. Pharmacokinet. 45:649-663.
21. Trifilio, S., G. Pennick, J. Pi, J. Zook, M. Golf, K. Kaniecki, S. Singhal, S. Williams, J. Winter, M. Tallman, L. Gordon, O. Frankfurt, A. Evens, and J. Mehta. 2007. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 109:1532-1535.
22. Trifilio, S., S. Singhal, S. Williams, O. Frankfurt, L. Gordon, A. Evens, J. Winter, M. Tallman, J. Pi, and J. Mehta. 2007. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant. 40:451-456.
23. Walsh, T. J., E. J. Anaissie, D. W. Denning, R. Herbrecht, D. P. Kontoyiannis, K. A. Marr, V. A. Morrison, B. H. Segal, W. J. Steinbach, D. A. Stevens, J. A. van Burik, J. R. Wingard, and T. F. Patterson. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.